

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**




Figure 1




Figure 2

**Gabapentin and Oxybutynin -
Isobologram using 43% Control
Bladder Capacity**




Figure 3

**Gabapentin and Oxybutynin -
Isobologram using 31% Control
Bladder Capacity**




Figure 4




Figure 5




Figure 6




Figure 7

Title: Methods for Treating Lower Urinary Tract Disorders Using $\alpha_2\delta$ Subunit Calcium Channel Modulators with Smooth Muscle Modulators

Inventor(s): Fraser *et al.*

Application No: Not yet assigned

Atty Dkt No: 046562/274660

8/23




Figure 8




Figure 9




Figure 10

Title: Methods for Treating Lower Urinary Tract Disorders Using $\alpha_2\delta$ Subunit Calcium Channel Modulators with Smooth Muscle Modulators

Inventor(s): Fraser *et al.*

Application No: Not yet assigned

Atty Dkt No: 046562/274660

11/23




Figure 11




Figure 12




Figure 13




Figure 14

Title: Methods for Treating Lower Urinary Tract Disorders Using $\alpha_2\delta$ Subunit Calcium Channel Modulators with Smooth Muscle Modulators

Inventor(s): Fraser *et al.*

Application No: Not yet assigned

Atty Dkt No: 046562/274660

15/23




Figure 15

Title: Methods for Treating Lower Urinary Tract Disorders Using $\alpha_2\delta$ Subunit Calcium Channel Modulators with Smooth Muscle Modulators

Inventor(s): Fraser *et al.*

Application No: Not yet assigned

Atty Dkt No: 046562/274660

16/23




Figure 16





Figure 17

**Theoretical Additive vs. Combination
Cat Data**



0.1/3, 0.3/10, 1/30 mg/kg Oxybutynin/Gabapentin

Figure 18

Oxybutynin in the Cat (n=5)




Figure 19A

Gabapentin in the Cat (n=5)




Figure 19B





Figure 20


**Combination
Oxybutynin/Gabapentin in
Chronic SCI Rats (n=3)**



$P=0.0278$ by Friedman Test from Low

Figure 21


Combination
Oxybutynin/Gabapentin in
Chronic SCI Rats (n=3)



P=0.0174 by Friedman Test from Veh 3

Figure 22

**Combination
Oxybutynin/Gabapentin in
Chronic SCI Rats (n=3)**



P=0.0017 by Freidman Test from Veh 3

Figure 23